Activity of osimertinib in a patient with stage IV non-small cell lung cancer harboring HER2 exon 19, p.L755P mutation: case report

BACKGROUND: Recurrent in-frame insertions within exon 20 causing duplication of amino acids Tyrosine-Valine-Methionine-Alanine (YVMA) represent 80% of all HER2 alterations in non-small cell lung cancer (NSCLC). HER2 tyrosine kinase inhibitors (TKI), anti-HER2 monoclonal antibodies and HER2 directed...

Descripción completa

Detalles Bibliográficos
Autores principales: Jonsdottir, Gudbjorg, Smith, Mark, Wood, Samuel, Hejleh, Taher Abu, Furqan, Muhammad
Formato: Online Artículo Texto
Lenguaje:English
Publicado: AME Publishing Company 2023
Materias:
Case Report
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183391/
https://www.ncbi.nlm.nih.gov/pubmed/37197637
http://dx.doi.org/10.21037/tlcr-22-596

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10183391/
https://www.ncbi.nlm.nih.gov/pubmed/37197637
http://dx.doi.org/10.21037/tlcr-22-596

Ejemplares similares